Fiche centre
Research site
Stavanger — Norway
Essais liés2clinical trials
VilleStavangerlocalisation
PaysNorwaylocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT02471560
Essais cliniques associés
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Trastuzumab deruxtecan | Parkinson | Phase 3 | NCT06989112 | DE-01 — DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer | RECRUITING |
| dimethyl fumarate | SEP | Phase 4 | NCT02471560 | TECONGUT — Tecfidera and the Gut Microbiota | COMPLETED |